Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind study of an adjuvanted recombinant RSV vaccine in adults
CTR20261694Phase 2Active
- Sponsor
- Ab&B Bio-tech Co., Ltd.
- Start
- May 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus lower respiratory tract infection, sponsored by Ab&B Bio-tech Co., Ltd.. Started May 2026; status: active.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on CTR20261694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261694.